Arrowhead to Present at Master Investor 2013
Master Investor 2013
PASADENA, Calif. -- April 24, 2013
Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics
company, today announced that its President and CEO, Dr. Chris Anzalone, will
present at Master Investor, the UK’s leading investment show, on Saturday,
April 27 at 2:05 p.m. BST at the Business Design Centre in London. Details can
be found on the event website at http://masterinvestor.co.uk/.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage targeted therapeutics
company with development programs in oncology, obesity, and chronic hepatitis
B virus infection. The company is leveraging its platform technologies to
design and develop peptide-drug conjugates (PDCs) that specifically home to
cell types of interest while sparing off-target tissues, create targeted drugs
based on the gene silencing RNA interference (RNAi) mechanism, and work with
partners to create improved versions of traditional small molecule drugs.
For more information please visit http://www.arrowheadresearch.com, or follow
us on Twitter @ArrowRes. To be added to the Company's email list to receive
news directly, please send an email to email@example.com.
Arrowhead Research Corporation
Vince Anzalone, CFA
The Trout Group
Press spacebar to pause and continue. Press esc to stop.